A single chain insulin agonist analog comprising the general structure B-LM-A wherein B represents an insulin B chain comprising the sequence R 22 -X 25 LCGX 29 X 30 LVX 33 X 34 LYLVCGX 41 X 42 GFX 45 (SEQ ID NO: 21); A represents an insulin A chain comprising the sequence GIVX 4 X 5 CCX 8 X 9 X 10 CX 12 LX 14 X 15 LX 17 X 18 X 19 CX 21 -R 13 (SEQ ID NO: 22); and LM represents a linking moiety linking the carboxy terminus of the B chain to the amino terminus of the A chain; wherein R 13 is COOH or CONH 2; X 4 is glutamic acid or aspartic acid; X 5 is glutamine or glutamic acid X 8 is histidine, threonine or phenylalanine; X 9 is serine, arginine, lysine, ornithine or alanine; X 10 is isoleucine or serine; X 12 is serine or aspartic acid X 14 is tyrosine, arginine, lysine, ornithine or alanine; X 15 is glutamine, glutamic acid, arginine, alanine, lysine, ornithine or leucine; X 17 is glutamine, glutamic acid, aparagine, aspartic acid or lysine, ornithine X 18 is methionine, asparagine, glutamine, aspartic acid, glutamic acid or threonine; X 19 is tyrosine, 4-methoxy-phenylalanine or 4-amino phenylalanine; X 21 is selected from the group consisting of alanine, glycine, serine, valine, threonine, isoleucine, leucine, glutamine, glutamic acid, asparagine, aspartic acid, histidine, tryptophan, tyrosine, and methionine; X 25 is selected from the group consisting of histidine and threonine; X 29 is selected from the group consisting of alanine, glycine and serine; X 30 is selected from the group consisting of histidine, aspartic acid, glutamic acid, homocysteic acid and cysteic acid; X 33 is selected from the group consisting of aspartic acid, glutamine, and glutamic acid; X 34 is selected from the group consisting of alanine and threonine; X 41 is selected from the group consisting of aspartic acid, asparagine and glutamic acid; X 42 is selected from the group consisting of alanine, lysine, ornithine and arginine; X 45 is selected from the group consisting of tyrosine, histidine, asparagine and phenylalanine; further wherein said linking moiety consists of an eight amino acid sequence of GX 52 GSSSRR (SEQ ID NO: 31), wherein X 52 is any amino acid other than tyrosine, or an amino acid sequence that differs from SEQ ID NO: 31 by a single amino acid substitution at any of positions 1, 3, 4, 5, 6, 7 or 8 of SEQ ID NO: 31; and R 22 is selected from the group consisting of AYRPSE (SEQ ID NO: 14), FVNQ (SEQ ID NO: 12), PGPE (SEQ ID NO: 11), a tripeptide glycine-proline-glutamic acid, a tripeptide valine-asparagine-glutamine, a dipeptide proline-glutamic acid, a dipeptide asparagine-glutamine, glutamine, glutamic acid and an N-terminal amine. R 13 is COOH or CONH 2; X 4 is glutamic acid or aspartic acid; X 5 is glutamine or glutamic acid X 8 is histidine, threonine or phenylalanine; X 9 is serine, arginine, lysine, ornithine or alanine; X 10 is isoleucine or serine; X 12 is serine or aspartic acid X 14 is tyrosine, arginine, lysine, ornithine or alanine; X 15 is glutamine, glutamic acid, arginine, alanine, lysine, ornithine or leucine; X 17 is glutamine, glutamic acid, aparagine, aspartic acid or lysine, ornithine X 18 is methionine, asparagine, glutamine, aspartic acid, glutamic acid or threonine; X 19 is tyrosine, 4-methoxy-phenylalanine or 4-amino phenylalanine; X 21 is selected from the group consisting of alanine, glycine, serine, valine, threonine, isoleucine, leucine, glutamine, glutamic acid, asparagine, aspartic acid, histidine, tryptophan, tyrosine, and methionine; X 25 is selected from the group consisting of histidine and threonine; X 29 is selected from the group consisting of alanine, glycine and serine; X 30 is selected from the group consisting of histidine, aspartic acid, glutamic acid, homocysteic acid and cysteic acid; X 33 is selected from the group consisting of aspartic acid, glutamine, and glutamic acid; X 34 is selected from the group consisting of alanine and threonine; X 41 is selected from the group consisting of aspartic acid, asparagine and glutamic acid; X 42 is selected from the group consisting of alanine, lysine, ornithine and arginine; X 45 is selected from the group consisting of tyrosine, histidine, asparagine and phenylalanine; further wherein said linking moiety consists of an eight amino acid sequence of GX 52 GSSSRR (SEQ ID NO: 31), wherein X 52 is any amino acid other than tyrosine, or an amino acid sequence that differs from SEQ ID NO: 31 by a single amino acid substitution at any of positions 1, 3, 4, 5, 6, 7 or 8 of SEQ ID NO: 31; and R 22 is selected from the group consisting of AYRPSE (SEQ ID NO: 14), FVNQ (SEQ ID NO: 12), PGPE (SEQ ID NO: 11), a tripeptide glycine-proline-glutamic acid, a tripeptide valine-asparagine-glutamine, a dipeptide proline-glutamic acid, a dipeptide asparagine-glutamine, glutamine, glutamic acid and an N-terminal amine.